Literature DB >> 22886612

The treatment of lower urinary tract symptoms in patients with multiple sclerosis: a systematic review.

A Tubaro1, F Puccini, C De Nunzio, G A Digesu, S Elneil, C Gobbi, V Khullar.   

Abstract

This is a systematic review on the treatment of lower urinary tract symptoms (LUTS) in patients with multiple sclerosis (MS). The heterogeneity of the outcome criteria did not allow a meta-analysis of the published evidence. In the last few decades, the therapeutic options for neurogenic bladder dysfunction have broadened. Despite this, no consensus has been reached as to the management of LUTD and LUTS in patients with MS, and the subject remains controversial. Bladder dysfunction is common in MS, affecting 80 %-100 % of patients during the course of the disease. Several studies have shown that urinary incontinence has a severe effect on patients' quality of life, with 70 % of patients classifying the impact bladder symptoms had on their life as "high" or "moderate." Moreover, the progressive feature of MS makes its treatment complex, since any achieved therapeutic result may be short-lived, with the possibility that symptoms will recur or develop de novo.

Entities:  

Mesh:

Year:  2012        PMID: 22886612     DOI: 10.1007/s11934-012-0266-9

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   3.092


  67 in total

1.  Pelvic floor muscle training in the treatment of lower urinary tract dysfunction in women with multiple sclerosis.

Authors:  Adélia Correia Lúcio; Renata Martins Campos; Maria Carolina Perissinotto; Ricardo Miyaoka; Benito Pereira Damasceno; Carlos Arturo Levi D'ancona
Journal:  Neurourol Urodyn       Date:  2010-11       Impact factor: 2.696

Review 2.  Neuromodulation 10 years on: how widely should we use this technique in bladder dysfunction?

Authors:  John F Bolton; Simon C W Harrison
Journal:  Curr Opin Urol       Date:  2009-07       Impact factor: 2.309

3.  Predictive factors for sacral neuromodulation in chronic lower urinary tract dysfunction.

Authors:  W A Scheepens; M M G J Jongen; F H M Nieman; R A de Bie; E H J Weil; P E V van Kerrebroeck
Journal:  Urology       Date:  2002-10       Impact factor: 2.649

Review 4.  Diagnosing detrusor sphincter dyssynergia in the neurological patient.

Authors:  Chasta-Dawne Bacsu; Lewis Chan; Vincent Tse
Journal:  BJU Int       Date:  2012-04       Impact factor: 5.588

5.  Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis.

Authors:  R B C Kavia; D De Ridder; C S Constantinescu; C G Stott; C J Fowler
Journal:  Mult Scler       Date:  2010-09-09       Impact factor: 6.312

Review 6.  Efficacy and adverse events of sacral nerve stimulation for overactive bladder: A systematic review.

Authors:  Nazema Y Siddiqui; Jennifer M Wu; Cindy L Amundsen
Journal:  Neurourol Urodyn       Date:  2010       Impact factor: 2.696

7.  Acute effect of posterior tibial nerve stimulation on neurogenic detrusor overactivity in patients with multiple sclerosis: urodynamic study.

Authors:  Sibel Canbaz Kabay; Mehmet Yucel; Sahin Kabay
Journal:  Urology       Date:  2008-04       Impact factor: 2.649

8.  The clinical and urodynamic results of a 3-month percutaneous posterior tibial nerve stimulation treatment in patients with multiple sclerosis-related neurogenic bladder dysfunction.

Authors:  Sahin Kabay; Sibel Canbaz Kabay; Mehmet Yucel; Hilmi Ozden; Zahide Yilmaz; Ozgen Aras; Bahar Aras
Journal:  Neurourol Urodyn       Date:  2009       Impact factor: 2.696

9.  A comparative study of pelvic floor muscle training in women with multiple sclerosis: its impact on lower urinary tract symptoms and quality of life.

Authors:  Adélia Correia Lúcio; Maria Carolina Perissinoto; Ricardo Aydar Natalin; Alessandro Prudente; Benito Pereira Damasceno; Carlos Arturo Levi D'ancona
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

10.  Botulinum injections for the treatment of bladder symptoms of multiple sclerosis.

Authors:  Vinay Kalsi; Gwen Gonzales; Roshni Popat; Apostolos Apostolidis; Sohier Elneil; Prokar Dasgupta; Clare J Fowler
Journal:  Ann Neurol       Date:  2007-11       Impact factor: 10.422

View more
  6 in total

Review 1.  OnabotulinumtoxinA (Botox(®)): a review of its use in the treatment of urinary incontinence in patients with multiple sclerosis or subcervical spinal cord injury.

Authors:  Mark Sanford
Journal:  Drugs       Date:  2014-09       Impact factor: 9.546

Review 2.  Regenerative medicine based applications to combat stress urinary incontinence.

Authors:  Hatim Thaker; Arun K Sharma
Journal:  World J Stem Cells       Date:  2013-10-26       Impact factor: 5.326

3.  Do Physical Therapy Interventions Affect Urinary Incontinence and Quality of Life in People with Multiple Sclerosis?: An Evidence-Based Review.

Authors:  Valerie Block; Monica Rivera; Marsha Melnick; Diane D Allen
Journal:  Int J MS Care       Date:  2015 Jul-Aug

4.  Coronavirus-induced demyelination of neural pathways triggers neurogenic bladder overactivity in a mouse model of multiple sclerosis.

Authors:  Matthew T McMillan; Xiao-Qing Pan; Ariana L Smith; Diane K Newman; Susan R Weiss; Michael R Ruggieri; Anna P Malykhina
Journal:  Am J Physiol Renal Physiol       Date:  2014-07-09

5.  The interactive web-based program MSmonitor for self-management and multidisciplinary care in multiple sclerosis: concept, content, and pilot results.

Authors:  Peter Joseph Jongen; Ludovicus G Sinnige; Björn M van Geel; Freek Verheul; Wim I Verhagen; Ruud A van der Kruijk; Reinoud Haverkamp; Hans M Schrijver; J Coby Baart; Leo H Visser; Edo P Arnoldus; H Jacobus Gilhuis; Paul Pop; Monique Booy; Wim Lemmens; Rogier Donders; Anton Kool; Esther van Noort
Journal:  Patient Prefer Adherence       Date:  2015-12-11       Impact factor: 2.711

6.  The prevalence of lower urinary tract symptoms based on individual and clinical parameters in patients with multiple sclerosis.

Authors:  Fatemeh Nazari; Vahid Shaygannejad; Mehrdad Mohammadi Sichani; Marjan Mansourian; Valiollah Hajhashemi
Journal:  BMC Neurol       Date:  2020-01-17       Impact factor: 2.474

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.